Replies to post #373864 on Amarin Corp Plc (AMRN)

[Whalatane]

RMB...well hopefully the stars are aligning .
If aspirin works in this population ...Vascepa has to work even better .
Kiwi

[Whalatane]

RMB. This aspirin trial is also being discussed on JAMA

Our subgroup analysis identified 2 groups that may benefit from early aspirin therapy.
Patients older than 60 years had significantly lower odds of in-hospital mortality, whereas those who were younger did not
. Given prior studies that have shown increased mortality with age, it is not surprising that aspirin’s efficacy may be greater in older patients.
The number of comorbidities also appeared to modify aspirin’s association with mortality.
Patients without comorbidities receiving early aspirin did not have lower odds of mortality, while those with at least 1 comorbidity had lower odds of mortality.
Several studies have found an association between the number of comorbidities and mortality in COVID-19, and the larger effect size of early aspirin in these subgroups with comorbidities is consistent with this pattern.

Should see more risk reduction with Vascepa in MITIGATE ...older population with multiple cormorbidities
JMO
Kiwi